Toleranzia develops drugs that utilize the immune system’s own intrinsic power to treat autoimmune orphan diseases. The drugs, which target the cause of the disease, can greatly alleviate or cure the disease and not, like current treatments, only reduce the symptoms. They have the potential to become the first long-acting or curative treatments that act specifically on the underlying cause of the autoimmune orphan disease they are developed for.
Toleranzia’s vision is to provide new medicines to treat and cure patients with autoimmune orphan diseases.
The company’s internal focus is on preclinical and early clinical research and development, in parallel with business development to find suitable partner for commercialization. Continued clinical development and commercialization will take place in partnership with leading pharmaceutical companies.
Main business-related goals
Toleranzia’s main focus is the autoimmune nerve and muscle disease myasthenia gravis (MG), for which the Company is developing the drug candidate TOL2. In addition, Toleranzia works with the autoimmune blood vessel disease ANCA vasculitis, for which the Company is developing the drug candidate TOL3. Both diseases are so-called orphan diseases (rare diseases) and for both there is a huge unmet medical need and a great market potential.
In parallel, the company also conducts academic and commercial collaborations in autoimmune diseases and continuously evaluates new cutting-edge technologies, as a way to maximize the value of the projects.